Preclinical studies have shown that blockade of TGF-β signaling, using small molecule inhibitors of TGF-β receptor I kinase activity, reduced melanoma and breast cancer bone metastasis and prolonged mouse survival [10-12]. This evidence concerns the gene TGFB1 and breast carcinoma.